EMA Rejects Bevacizumab Drug For Use In Wet AMD
European Commission Approves COVID-19 Products Ronapreve & Regkirona
Executive Summary
Nearly a year and a half after it was filed for approval, the EU regulator has rejected a mystery injectable product containing the monoclonal antibody bevacizumab for ophthalmic use.
You may also be interested in...
All Eyes On Pricing Model As EU Crunch Time Nears For First Ophthalmic Bevacizumab
If Outlook Therapeutics’ Lytenava secures EU approval for wet AMD, the company says it expects to price the drug as a lower cost alternative to biosimilars and premium branded products for the condition, and higher than off-label compounds.
All Eyes On Pricing Model As EU Crunch Time Nears For First Ophthalmic Bevacizumab
If Outlook Therapeutics’ Lytenava secures EU approval for wet AMD, the company says it expects to price the drug as a lower cost alternative to biosimilars and premium branded products for the condition, and higher than off-label compounds.
Outlook To Make Its Case For Ophthalmic Bevacizumab At High-Stakes EMA Meeting
Outlook Therapeutics is hoping to secure EU marketing approval for the first ophthalmic formulation of bevacizumab.